



32ND ANNUAL MEETING

Preliminary Program

All meetings and activities will take place at the Prague Congress Centre unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.isHLT.org) for updates. The Final Program, which is distributed on site, will reflect the latest session schedule and room assignments.

TUESDAY, APRIL 17, 2012

7:00 am – 8:00 pm
SPEAKER READY ROOM OPEN

7:30 am – 7:30 pm
ISHLT ACADEMY: MECHANICAL
CIRCULATORY SUPPORT

8:00 am – 1:00 pm
ISHLT BOARD OF DIRECTORS
MEETING

2:00 pm – 6:00 pm
ISHLT COMMITTEE MEETINGS

5:00 pm – 8:00 pm
REGISTRATION DESK OPEN

WEDNESDAY, APRIL 18, 2012

7:00 am – 6:00 pm
SPEAKER READY ROOM OPEN

7:00 am – 6:00 pm
REGISTRATION DESK OPEN

PRE-MEETING SYMPOSIA | Wednesday**8:00 am – 9:30 am****FORUM HALL****SYMPOSIUM 1*****Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support*****CHAIRS:** David S. Feldman, MD, PhD, FAHA, FACC and Ugolino Livi, MD, FECTS

Session Summary: The success of LVAD therapy often depends on the right ventricle. A better understanding of the risk of RV failure after implant is needed. An overview of different RV risk assessment approaches before LVAD implant will be discussed during this session. The speakers will also address medical and mechanical therapies for the failing right ventricle. The speakers will review existing evidence and present clinical scenarios, helping the clinician establish a comprehensive and successful management plan for patients at risk of right heart failure after LVAD implant.

8:00 am *Predicting Right Heart Failure after LVAD Implant*, Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:15 am *RV Dysfunction in MCS: What is the Transcript Signature of RV/LV in Mechanically Assisted Patients?*, J. Eduardo Rame, MD, Mphil, University of Pennsylvania, Philadelphia, PA

8:30 am *Three Perspectives: Patient with a Failing RV*

8:30 am *Triage with Medicines*, Michael M. Givertz, MD, Brigham & Women's Hospital, Boston, MA

8:40 am *Triage with BiVADs*, Thomas Krabatsch, MD, PhD, Deutsches Herzzentrum Berlin, Germany

8:50 am *TAH is It*, Vigneshwar Kasirajan, MD, Virginia Commonwealth University Medical Center, Richmond, VA

9:00 am *Right Heart Failure Late after LVAD Implant*, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada

9:15 am *Panel Discussion*

MEETING HALL I**SYMPOSIUM 2*****Past, Present and Future of Cardiac Allograft Surveillance*****CHAIRS:** Maria Frigerio, MD and Keyur B. Shah, MD

Session Summary: The pattern and clinical manifestations of acute rejection has changed greatly during the last two decades. Endomyocardial biopsy was developed as the gold standard for the diagnosis, but recently non-invasive molecular-based approaches have been developed. This session will review the usefulness and pitfalls of endomyocardial biopsy monitoring in current clinical practice, and what is realistic about everyday use of genomics and proteomics-based methodologies.

8:00 am *The Changing Epidemiology of Acute Rejection*, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

8:20 am *The Genomics of Rejection*, Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

8:40 am *The Proteomics of Rejection*, Bruce McManus, MD, PhD, FRCS, FCAHS, St. Paul's Hospital, Vancouver, Canada

9:00 am *Integrating Invasive and Non-Invasive Tools: A Clinician's Perspective*, Sharon A. Hunt, MD, Stanford University Medical Center, Stanford, CA

9:20 am *Question and Answer*

PANORAMA HALL**SYMPOSIUM 3*****Evolving Concepts of Chronic Lung Allograft Dysfunction*****CHAIRS:** Keith C. Meyer, MD, MS and Paul A. Corris, MD, FRCP

Session Summary: This session will present and discuss new concepts of chronic lung allograft dysfunction and will reflect some of the conclusions and recommendations reached by the joint ISHLT/ATS/ERS task force on care of the lung transplant recipient.

8:00 am *BOS: Definitions and Emerging Phenotypes*, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

8:25 am *Emerging Pathways in BOS: Autoimmunity*, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN

8:40 am *Emerging Pathways in BOS: Epithelial – Mesenchymal Transition*, Daniel C. Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

9:00 am *Future Therapies for BOS*, Andrew J. Fisher, FRCP, PhD, FRCP, Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

9:30 am – 9:45 am COFFEE BREAK

PRE-MEETING SYMPOSIA | Wednesday

8:00 am – 9:30 am

MEETING HALL IV

SYMPOSIUM 4

Cardiogenic Shock Before and After Heart Transplantation

CHAIRS: Nader Moazami, MD and Nicholas G. Smedira, MD

Session Summary: Cardiogenic shock before and after heart transplantation has for many years been a challenging problem, and the outcomes are still not optimal. The goal – to save the patient's life – has not changed, but the treatment options have. The participants will learn about options, from ECMO to total artificial heart, that are available for "bridge to bridge" and "bridge to decision" in severe cardiogenic shock before and after heart transplantation. Simple questions such as "what to implant and how," "how long to treat," "where to go" and "when to stop" will be discussed by experienced experts in the field. These questions will hit you unexpectedly in the middle of the night so be prepared. Join us in Prague!

8:00 am *Cardiogenic Shock – How Long Should Be the ECMO Bridge?*, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA

8:12 am *What is the Direction of the Bridge in Cardiogenic Shock?*, Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere, Paris, France

8:24 am *Extracorporeal Mechanical Support and the Community Hospitals: How to Make it Work*, Christoph Schmid, MD, University Medical Center Regensburg, Regensburg, Germany

8:36 am *What is the Best Surgical Option in the Setting of Primary Graft Failure?*, Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

8:48 am *Surgical Technique of ECMO Placement – Balance between Invasiveness and Effectiveness*, Arnt E. Fiene, MD, Rikshospitalet, Oslo, Norway

9:00 am *TAH – Standard Solution in Shock?*, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany

9:12 am *Panel Discussion*

MEETING HALL V

SYMPOSIUM 5

Potpourri of Special Topics in Pulmonary Hypertension

CHAIRS: Raymond L. Benza, MD and Fernando Torres, MD

Session Summary: This session will include a potpourri of topics on pulmonary hypertension that are less understood and of interest to cardiologists, pulmonary/critical care specialists, anesthesiologists and surgeons.

8:00 am *Schistosomiasis: Possibly the Most Common Worldwide Cause of Pulmonary Hypertension – What Is It and How Do We Diagnose and Treat It?*, Rogerio Souza, MD, PhD, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil

8:18 am *Understanding the Many Faces of Sarcoidosis and Its Relationship to Pulmonary Hypertension*, Christopher F. Barnett, MD, MPH, University of California, San Francisco / San Francisco General Hospital, San Francisco, CA

8:36 am *Pre-Operative Evaluation and Intra-Operative Management of the Pulmonary Hypertensive Patient*, Dana P. McGlothlin, MD, University of California San Francisco Medical Center, San Francisco, CA

8:54 am *Critical Care Management of the Pulmonary Hypertensive Patient: Optimal Use of Inotropes, Pressors and Pulmonary Vasodilators*, Myung H. Park, MD, FACC, University of Maryland School of Medicine, Baltimore, MD

9:13 am *Future of Pulmonary Arterial Hypertension Treatment – Should We Really Be Thinking Like the Oncologists?*, Marc Humbert, MD, PhD, Universite Paris-Sud, Paris, France

NORTH HALL

SYMPOSIUM 6

Neurocognitive, Psychosocial and Behavioral Issues in Children and Adolescents

CHAIRS: Kathleen L. Grady, PhD, APN and Susan M. Chernenko, RN, MN, NP

Session Summary: This session addresses non-clinical issues (psychosocial, behavioral and neurocognitive) in children after heart transplantation. Children and adolescents frequently have developmental challenges in these areas, including early after transplant through the time they transition to adult programs and clinicians need to learn more about identifying these concerns and how best to intervene on behalf of these children in practice settings. Thus, there is also a need for future research to better understand these issues, test interventions and inform best practices.

8:00 am *Neurocognition: What Happens after Thoracic Transplantation in Children and Adolescents?*, Richard E. Chinnock, MD, Loma Linda University Children's Hospital, Loma Linda, CA

8:12 am *Helping Children Make Psychosocial and Educational Adjustments after Transplantation*, Connie White-Williams, PhD, RN, FAAN, University of Alabama at Birmingham, AL

8:24 am *Adolescence and Adherence: The Perfect Storm*, Sabina De Geest, PhD, RN, University of Basel, Switzerland

8:36 am *Parenting Children with Thoracic Transplantation: Stress, Coping and Letting Go*, Diana A. Shellmer, PhD, Children's Hospital of Pittsburgh at UPMC / Univ. of Pittsburgh, Pittsburgh, PA

8:48 am *No Longer a Child – Not Quite an Adult: How to Help the Adolescent Recipient Transition to Adulthood*, Elfriede Pahl, MD, Children's Memorial Hospital, Chicago, IL

9:00 am *Quality of Life in Pediatric Thoracic Transplantation: Trading One Illness for Another*, Jo Wray, PhD, Great Ormond Street Hospital for Children, London, United Kingdom

9:12 am *Panel Discussion*

9:30 am – 9:45 am COFFEE BREAK

PRE-MEETING SYMPOSIA | Wednesday**9:45 am – 11:15 am****FORUM HALL****SYMPOSIUM 7***New Devices, New Approaches***CHAIRS:** Matthias Loebe, MD, PhD and Martin Strueber, MD

Session Summary: This session will explore new developments in LVADs and their clinical applications. It will start with a topic on axial vs. centrifugal continuous flow pumps and pros and cons of each technology in rendering a successful LVAD therapy. Furthermore, an emerging topic of how much support, partial vs. full, might be ideal will be considered. Then, a role of LVAD therapy in patients with diastolic heart failure will be reviewed. Finally, how the future in treating patients with advanced heart failure might be shaped by stem cell, transgenic xenotransplantation or LVAD will be presented.

9:45 am Axial vs. Centrifugal Pumps, Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI

9:57 am LVAD: Partial vs. Full Flow Support?, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

10:09 am VAD Therapy in Heart Failure with Preserved Systolic Function, Soon J. Park, MD, Mayo Clinic, Rochester, MN

10:21 am Machine or Biology? The Future for a Patient with a Failing Heart is with Machines, James K. Kirklin, MD, University of Alabama at Birmingham, AL

10:33 am Machine or Biology? The Future for a Patient with a Failing Heart is with Stem Cells, Andre Terzic, MD, PhD, Mayo Clinic, Rochester, MN

10:45 am Machine or Biology? The Future for a Patient with a Failing Heart is with Xenotransplantation, Christopher McGregor, MB, FRCS, MD(Hons), Mayo Clinic and University College London, Rochester, MN, USA and London, United Kingdom

10:57 am Panel Discussion

MEETING HALL I**SYMPOSIUM 8***AMR Part 1 – The ABCs of AMR: Antibodies, B Cells, Complement/Coagulation***CHAIRS:** Gerald J. Berry, MD and Thalachallour Mohanakumar, PhD

Session Summary: This first of two AMR sessions will begin with brief clinical case presentations of antibody-mediated rejection in the setting of heart and lung transplantation to set the stage. This will be followed by an overview of our current understanding of the key immune mediators of AMR, leading to the formulation of rational management strategies with emerging therapeutics.

9:45 am Clinical Context Case Presentations, Luciano Potena, MD, PhD, University of Bologna, Italy and Todd L. Astor, MD, Massachusetts General Hospital, Boston, MA

9:55 am B Cells/Plasma Cells, Esme Dijke, PhD, University of Alberta, Edmonton, Canada

10:15 am Complement and Coagulation, Stephen Sacks, MD, PhD, MRC Centre for Transplantation, King's College, London, United Kingdom

10:35 am A Rational Approach to Treatment Strategies, Richard Kirk, MA FRCP FRCPCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:05 am Discussion

PANDRAMA HALL**SYMPOSIUM 9***Ex-Vivo Perfusion of Heart and Lungs – Why, With What and How?***CHAIRS:** Dirk Van Raemdonck, MD, PhD and Steven S.L. Tsui, MD, FRCS

Session Summary: The session will discuss the emerging area of ex-vivo perfusion of hearts and lungs for preservation or resuscitation. The session will open with an expert speaking about machine perfusion of kidneys as there are significantly more data with the kidney than thoracic organs and provides a nice background for subsequent discussion regarding hearts and lungs.

9:45 am Part I: Kidney – Ex-Vivo Machine Perfusion of Kidneys, Rutger J. Ploeg, MD, PhD, FRCS, University of Oxford, United Kingdom

10:00 am Part II: Heart – Ex-Vivo Perfusion of Hearts with the Transmedics Device – European Experience, Christoph Knosalla, MD, PhD, Deutsches Herzzentrum Berlin, Germany

10:15 am Ex-Vivo Perfusion of Hearts With The Transmedics Device – U.S. Experience, Abbas Ardehali, MD, University of California Los Angeles School of Medicine, Los Angeles, CA

10:30 am Part III: Lung – Clinical Experience with Warm Asanguinous Ex-Vivo Lung Perfusion in Toronto, Shaf Keshavjee, MD, FRCS, Toronto General Hospital, Toronto, Canada

10:45 am Clinical Experience with Asanguinous Ex-Vivo Lung Perfusion Utilizing the Vivoline System, Stephen C. Clark, BMedSci(Hons), BM, BS, DM, FRCS(C-Th), Freeman Hospital, Newcastle Upon Tyne, United Kingdom

10:57 am Clinical Experience with Warm Blood Lung Perfusion – Transmedics, Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

11:09 am Discussion

11:15 am – 11:30 am COFFEE BREAK

PRE-MEETING SYMPOSIA | Wednesday

9:45 am – 11:15 am

MEETING HALL IV

SYMPOSIUM 10

The Right Ventricle and Pulmonary Vascular Load in Health and Disease

CHAIRS: Marc Humbert, MD and John T. Granton, MD

Session Summary: In this session, we will present the state-of-the-art understanding of right ventricular (RV) function in four distinct states: 1) health, 2) exercise, 3) resting pulmonary hypertension and 4) right heart failure. The goal of the session is to review the anatomy and physiology of the RV in health and exercise along with the pathophysiology and therapy in disease states. Further, we will present data on novel assessment of RV function using both non-invasive and invasive modalities and discuss management principles and practice. We will address the educational need currently present in the understanding of normal and abnormal RV function, standard and novel modalities of RV assessment, and importantly, management of RV failure.

9:45 am *The Right Ventricle in Health*, Ryan J. Tedford, MD, Johns Hopkins Medical Institutions, Baltimore, MD

10:05 am *The Right Ventricle in Exercise*, Rajeev Sagar, MD, Heart-Lung Institute, St. Joseph Hospital & Medical Center, Phoenix, AZ

10:20 am *Pathophysiology of RV Failure*, Stephen C. Mathai, MD, MHS, Johns Hopkins University, Baltimore, MD

10:35 am *Assessment and Management of RV Failure*, Anton Vonk-Noordegraaf, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands

11:00 am *Panel Discussion*

MEETING HALL V

SYMPOSIUM 11

MCS in Congenital Heart Disease & Pediatrics

CHAIRS: Ivan M. Rebeyka, MD and Christopher Almond, MD, MPH

Session Summary: This symposium focuses on current approaches to long-term MCS in children and adults with congenital heart disease, including single ventricle pathology. In six talks given by highly experienced physicians from the US, Canada and Europe, MCS options, implantation techniques, available devices and the perspective of patients with end-stage congenital heart disease will be addressed. In addition, panel discussions will offer you the unique possibility to discuss your burning questions. So join us in Prague!

9:45 am *Implantable VADs in Children and Adults with Congenital Heart Disease*, David Morales, MD, Texas Children's Hospital and Baylor College of Medicine, Houston, TX

9:57 am *Is Two Better than One? Indications for Bi iVAD vs. LVAD Placement in Children*, Holger W. Buchholz, MD, University of Alberta, Stollery Children's Hospital and Mazankowski Alberta Heart Institute, Edmonton, Canada

10:09 am *Beyond the Surgery – Preventing Thromboembolic Complications During Long-Term VAD Support*, M. Patricia Massicotte, MSc, MD, MHSc, University of Alberta/Stollery Children's Hospital, Edmonton, Canada

10:21 am *VAD Options for the Single Ventricle Patient*, Olaf Reinhartz, MD, Stanford University, Stanford, CA

10:33 am *Heart Transplant or VAD in Children and Adults with Congenital Heart Disease – Strategies for Improving Transplant Outcome*, Robert Jaquiss, MD, Duke University School of Medicine, Durham, NC

10:45 am *Going Home: Hospital Discharge on VAD Support in Children*, William Neil Wrightson, RN, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

10:57 am *Panel Discussion*

NORTH HALL

SYMPOSIUM 12

CMV and Beyond: Important Viruses in Thoracic Transplantation

CHAIRS: Martha L. Mooney, MD and Martin R. Zamora, MD

Session Summary: This session presents the latest insights in the significance of important viral pathogens in thoracic transplantation. Current data regarding monitoring, prevention and treatment strategies for viruses after transplantation will be addressed. The use of emerging technologies to monitor for respiratory viruses and to assess for cytomegalovirus-specific immune function will be highlighted. Also other herpes viruses such as EBV and Herpes 6, 7 and 8 will be discussed. The strategies to control these viruses will be discussed. Also the question will be raised whether just viral load monitoring is sufficient to handle the patient. In addition, the question of HIV+ candidates will be addressed in the context of thoracic transplantation.

9:45 am *EBV Infection and PTLD: Beyond the Viral Load*, Steven A. Webber, MBChB, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA

10:00 am *Respiratory Viruses: Beyond RSV*, Peter M. Hopkins, MBBS FRACP HONOURS, The Prince Charles Hospital, Brisbane, Australia

10:15 am *Beyond Abdominal Organs: HIV+ Thoracic Transplant Candidates*, Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy

10:30 am *Beyond HSV: Human Herpes Viruses in Transplantation*, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

10:45 am *Beyond Prophylaxis: CMV Immune Monitoring*, Martina Sester, PhD, Saarland University, Homburg, Germany

11:00 am *Panel Discussion: CMV & Beyond: Clinical Dilemmas in Thoracic Transplant Recipients*

MODERATORS: Martin R. Zamora, MD and Camille N. Kotton, MD, FIDSA

11:15 am – 11:30 am COFFEE BREAK

PRE-MEETING SYMPOSIA | Wednesday**11:30 am – 1:00 pm****FORUM HALL****SYMPOSIUM 13***The Longer the Better – Chronic Medical Management of MCS***CHAIRS:** Evgenij V. Potapov, MD, PhD and Sudhir S. Kushwaha, MD

Session Summary: The increasing worldwide burden of advanced heart failure coupled with limitations in organ donors has led to an exponential rise in use of MCS. The INTERMACS registry shows a marked increase in MCS for the destination therapy indication. VAD recipients are increasingly being managed in the clinic environment. This session is designed for the learner to gain a better understanding of how to optimize long-term MCS in the clinic. Specific topics will address how to fine tune pump performance, how to manage post VAD arrhythmia, how to diagnose and manage aortic regurgitation and how to manage/prevent driveline and deeper pocket infections in VAD recipients. Finally, how to recognize risk and prevention of GI bleeding will be discussed.

11:30 am Fine Tuning Pump Performance, Mark S. Slaughter, MD, University of Louisville, Louisville, KY

11:42 am Arrhythmia Management: Beyond Amiodarone, Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, AL

11:54 am Aortic Insufficiency: An Achilles Heel for Long-Term Support?, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

12:06 pm Long-Term Infection Prevention, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

12:18 pm G.I. Bleeding: What is the Optimal Strategy for Diagnosis and Management?, Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA

12:30 pm Getting Back to Life: Sex, Driving and Rock-n-Roll – What, if Any, Restrictions are Reasonable?, Karl E. Nelson, Integris Baptist Medical Center, Oklahoma City, OK

12:42 pm Panel Discussion

MEETING HALL I**SYMPOSIUM 14***AMR Part 2 - The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy and Finally, the Patient***CHAIRS:** Allan R. Glanville, MBBS, MD, FRACP and Jon Kobashigawa, MD

Session Summary: This second AMR session will cover advances in antibody detection and pathologic parameters of diagnosis, and bring all aspects together for clinical correlation and future directions.

11:30 am Antibody Detection, Dolly B. Tyan, PhD, D(ABHI) Stanford University, Stanford, CA

12:00 pm Pathology: New Nomenclature/Classification, Charles C. Marboe, MD, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY

12:30 pm Clinical Correlate: What Does It All Mean? What are the Big Unanswered Questions?

Lung: Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

Heart: A. G. Kfoury, MD, FACC, Intermountain Medical Center (UTAH Cardiac Transplant Program), Murray, UT

PANDRAMA HALL**SYMPOSIUM 15***Advances in Pulmonary Transplant Surgery***CHAIRS:** Stephen C. Clark, BMed-Sci(Hons), BM, BS, DM, FRCS(C-Th) and Christopher H. Wigfield, MD, FRCS

Session Summary: This symposium covers advances in surgical techniques in lung transplantation. The goals of this session are to discuss three distinct areas where significant surgical developments have been made.

11:30 am Airway Complications, Michael S. Mulligan, MD, University of Washington, Seattle, WA

12:00 pm Mechanical Bridging to Lung Transplantation, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

12:30 pm Practical Issues with EVLP, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

1:00 pm – 3:00 pm LUNCH BREAK

PRE-MEETING SYMPOSIA | Wednesday

11:30 am – 1:00 pm

MEETING HALL IV

SYMPOSIUM 16

Thoracic Organ Donors: Optimal Management and New Avenues

CHAIRS: Kenneth R. McCurry, MD and Gregory Snell, MD

Session Summary: In this session, an overview is given on what is believed to be the optimal treatment strategy to maximally increase the thoracic organ yield from the multi-organ donor. In addition, perspectives to increase the number of lungs and hearts from donors deceased after cardiac death are discussed.

11:30 am *The Impact of Brain Death in Thoracic Organ Donor*, Arne P. Neyrinck, MD, University Hospitals Leuven, Belgium

11:40 am *Hormonal Therapy in Thoracic Organ Donor: Does It Work?*, Robert S. Bonser, MD, FRCS, FRCP, Queen Elizabeth Hospital Birmingham, United Kingdom

12:00 pm *Ventilatory Strategies and Inhaled Therapies to Increase Donor Lung Yield*, Lorraine B. Ware, MD, Vanderbilt University, Nashville, TN

12:20 pm *The Agonal Phase in Controlled Donation after Cardiac Death: Does it Matter?*, David V. Pilcher, MD, The Alfred Hospital, Melbourne, Australia

12:40 pm *Potential for Heart Transplantation from Donors after Cardiac Death?*, Stephen R. Large, MA, MS, FRCS, FRCP, MBA, Papworth Hospital, Cambridge, United Kingdom

MEETING HALL IV

SYMPOSIUM 17

Innate Immunity in Cardiothoracic Transplantation

CHAIRS: Susan Moffatt-Bruce MD and Daniel R. Goldstein, MD

Session Summary: The importance of the role of innate immunity in cardiothoracic transplantation is increasingly recognized. Innovative modalities for studying innate immunity are emerging. This session will cover the major mediators of damage from this arm of the immune system and their role in heart and lung transplantation.

11:30 am *Acute Lung Injury after Lung Transplantation*, Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO

11:50 am *Imaging the Innate Immune System after Lung Transplantation*, Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO

12:10 pm *Clinical Markers of Innate Immunity after Lung Transplantation*, Jason D. Christie, MD, MS, University of Pennsylvania School of Medicine, Philadelphia, PA

12:30 pm *Role of NK Cells and Neutrophils Cardiac Allograft Dysfunction*, Joren C. Madsen, MD, PhD, Massachusetts General Hospital, Boston, MA

12:50 pm *Panel Discussion*

NORTH HALL

SYMPOSIUM 18

Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients

CHAIRS: Christian Benden, MD and Dana McGlothlin, MD

Session Summary: Pulmonary hypertension associated with congenital systemic to pulmonary shunts is a growing indication for thoracic organ transplantation. This session aims to improve the understanding of congenital shunt physiology as it relates to pulmonary hypertension, review indications for and potential consequences of shunt closure, discuss the challenges of medical and surgical management of patients with Eisenmenger's syndrome and consider the use of pulmonary vasodilator therapy in this population. Finally the pros and cons of early referral for transplantation (with high operative mortality but generally good long term results) vs. multiple palliative procedures and surgeries will be addressed.

11:30 am *Congenital Heart Disease and Pulmonary Hypertension: Classification and Understanding Why All Defects are Not the Same*, Ian Adatia, MBChB, MRCP, FRCP(C), University of Alberta, Edmonton, Canada

11:45 am *Unrepaired Systemic to Pulmonary Shunts and PAH: To Close Or Not to Close?*, Daphne T. Hsu, MD, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY

12:00 pm *Medical Management of CHD Associated PAH: Do's and Don'ts for this Challenging Population*, Richard Krasuski, MD, The Cleveland Clinic, Cleveland, OH

12:15 pm *Use of PAH Directed Therapies in Patients with Single Ventricles*, Brian D. Hanna, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

12:30 pm *Balancing the Risks of Transplantation for CHD: A Last Resort After Multiple Palliative Procedures or An Early Referral?* Jonathan M. Chen, MD, New York Presbyterian Hospital, New York, NY

12:45 pm *Panel Discussion*

1:00 pm – 3:00 pm LUNCH BREAK

1:15 pm – 2:45 pm COUNCIL MEETINGS

3:00 pm – 4:15 pm CONCURRENT
ABSTRACT
SESSIONS

4:15 pm – 4:45 pm COFFEE BREAK

4:15 pm – 7:00 pm EXHIBIT HALL OPEN
POSTER VIEWING

PLENARY SESSION | Wednesday

4:45 pm – 6:00 pm

CONGRESS HALL

OPENING PLENARY SESSION

Overcoming Political Barriers

CHAIRS: Jan Pirk, MD, John Dark, MB, FRCS
and John B. O'Connell, MD

Session Summary: Prague serves as a showcase for the positive changes that have occurred in Eastern Europe following the demise of the iron curtain. This plenary session will open with welcomes from ISHLT President Lori West and Czech Republic Minister of Foreign Affairs Karel Schwarzenberg. Highlights include a historical perspective of Prague through the years followed by a description of the successful development of a lung transplant program in Prague. The session will close with a keynote address from internationally acclaimed physicist, commentator and essayist Lawrence Krauss who will speak on the impact of politics on scientific advancement.

4:45 pm Introduction and Welcome, Lori J. West, MD, DPhil, FRCPC, ISHLT President, University of Alberta, Edmonton, Canada

4:50 pm Welcome, Karel Schwarzenberg, Deputy Prime Minister and Minister of Foreign Affairs, Czech Republic

5:00 pm Bringing Down the Walls: A Historical Perspective, Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT

5:15 pm After the Iron Curtain: Successes of Regional Collaboration in Thoracic Transplantation, Prof. Walter Klepetko, MD, Medical University of Vienna, Austria

5:25 pm Political Influence and Scientific Advancement, Lawrence Krauss, PhD, School of Earth and Space Exploration, Arizona State University, Phoenix, AZ

6:00 pm – 7:00 pm EXHIBIT HALL OPENING
RECEPTION
POSTER VIEWING

THURSDAY, APRIL 19, 2012

7:00 am – 6:00 pm SPEAKER READY
ROOM OPEN

7:00 am – 6:00 pm REGISTRATION DESK OPEN

8:00 am – 9:15 am CONCURRENT
ABSTRACT
SESSIONS



CONCURRENT SYMPOSIA | Thursday

8:00 am – 9:15 am

MEETING HALL IV

CONCURRENT SYMPOSIUM 1

A Lifecycle Journey in Advanced Heart Failure and Transplantation

CHAIRS: Patricia A. Uber, PharmD and Andreas Zuckermann, MD

PANEL DISCUSSANTS:

Patricia A. Uber, PharmD, University of Maryland, Baltimore, MD
Andreas Zuckermann, MD, Medical University of Vienna, Austria
Paul E. Nolan, Jr., PharmD, University of Arizona, Tucson
David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH
Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA
Robert Lee Page, II, PharmD, MSPH, University of Colorado, Denver, CO
Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC

Session Summary: This is the inaugural symposium in a series entitled “A Lifecycle Journey in...” sponsored by the ISHLT Pharmacy and Pharmacology Council. This series envisions using an enduring case to create a panel facilitated and audience supported best practice based discussion at predefined key “journey intervals.” The focus of this series will be on therapeutic aspects that uniquely involve emerging or established knowledge in the pharmacology and pharmacy aspects of the interval disease states or situations.

In this session the focus will be on the lifecycle of Advanced Heart Failure and Cardiac Transplantation with special emphasis on the “journey points” of Mechanical Circulatory Support and anticoagulation, post-transplant development of Antibody Mediated Rejection and late complications that demand innovative immunosuppressive strategies.

8:00 am Pre-Transplant Journey: Advanced Heart Failure with BTT MCS and Malfunction Due to Thrombosis, Paul E. Nolan, Jr., PharmD, University of Arizona, Tucson, AZ

8:20 am Early Post-Transplant Journey: Primary Graft Failure at 1 Week, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

8:40 am Late Post-Transplant Journey: Development of Skin Cancer and Pre-cancerous Colon Polyp, Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA

9:00 am Panel and Audience Questions and Answers

9:00 am – 5:00 pm EXHIBIT HALL OPEN

9:15 am – 9:45 am COFFEE BREAK

PLENARY SESSION | Thursday

9:45 am – 11:45 am

CONGRESS HALL

PLENARY SESSION

ISHLT Traditions

CHAIRS: Stuart C. Sweet, MD, PhD and Lori J. West, MD, DPhil, FRCPC

Session Summary: This traditional ISHLT plenary will include an address from ISHLT President Lori West, Reports from the Thoracic Organ and Mechanical Circulatory Support Registries, and the presentation of a Lifetime Achievement Award. The plenary session will feature Luc Noel MD, Coordinator, Clinical Procedures Department of Essential Health Technologies Health Systems and Services, World Health Organization. Dr. Noel will discuss how transplant professionals can aid in the efforts led by the World Health Organization to raise awareness of access, safety and ethical issues in cell, tissue and organ transplantation.

9:45 am Welcome and Program Chair’s Report, Stuart C. Sweet, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO

9:55 am President’s Address, Lori J. West, MD, DPhil, FRCPC, ISHLT President, University of Alberta, Edmonton, Canada

10:05 am Thoracic Registry Report, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

10:25 am MCS Registry Reports, James K. Kirklin, MD, University of Alabama at Birmingham, AL

10:35 am The Responsibility of Transplantation Specialists in the World Health Assembly’s Vision for Transplantation, Dr. Luc Noel, Coordinator of Clinical Procedures, World Health Organization, Geneva, Switzerland

10:55 am Lifetime Achievement Award

11:45 am – Noon

**COFFEE BREAK
VISIT EXHIBITS
VIEW POSTERS**

Noon – 1:15 pm

**CONCURRENT ABSTRACT
SESSIONS**

CONCURRENT SYMPOSIA | Thursday

Noon – 1:15 pm

MEETING HALL V

CONCURRENT SYMPOSIUM 2*Focus On Caregivers: Investing in Our Patients' Future***CHAIRS:** Michael Petty, PhD, RN, CCNS, ACNS-BC and Sharon Beer, RN, MSc

Session Summary: Caregiving provided to adults in the United States alone represents more than \$37 billion in unreimbursed care provided by volunteer family caregivers and friends. It is well recognized that support for patients following heart transplant, lung transplant, or MCS implantation is a crucial component for ongoing patient success. Similarly, the challenges facing caregivers of patients with end-stage heart or lung disease can reflect years of steadily worsening health and stress for the family unit. Yet since the caregiver is not "our patient," we have paid inadequate attention to these central members of each patient's health care team. We have an incomplete understanding of their needs and an associated lack of an organized and individualized plan to address those needs. In this session the speakers will present current evidence regarding the problems encountered by those caregivers and will discuss unique approaches to address the special needs of the caregiver in the context of their providing care to the organ or device candidate or recipient.

Noon Family Caregivers of Mechanical Circulatory Support Patients, Judy A. Currey, PhD, Alfred/Deakin Nursing Research Center, Melbourne, Australia

12:12 pm Family Caregivers of Heart Transplant Candidates and Recipients, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

12:24 pm Family Caregivers of Lung Transplant Candidates and Recipients, Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

12:36 pm Family Caregivers of Children with End-Stage Heart and Lung Disease and Thoracic Transplant, Paula A. Kofflin, RN, BSN, CCTC, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN

12:48 pm Burdens of Family Caregivers as Surrogate Decision-Makers, Denise Dudzinski, PhD, MTS, University of Washington, Seattle, WA

1:00 pm Panel Discussion

3:15 pm – 4:30 pm

CONGRESS HALL

CONCURRENT SYMPOSIUM 3*Mechanical Circulatory Support – When is it Too Soon or Too Late?***CHAIRS:** Jan Pirk, MD and Stuart D. Russell, MD

Session Summary: MCS implant for bridge to transplant, recovery or destination therapy is steadily increasing. In order to obtain the best results after implant, patient and device selection are critical. This symposium will provide the participant with the latest information on patient selection for device therapy at both ends of the heart failure spectrum – specifically when is a patient too sick to receive a VAD and how early in the HF disease trajectory can we consider VAD implant. The session will close with a provocative discussion about VAD versus transplant and whether or not the time has come to change the definitive therapy for advanced HF from transplant to VAD alone.

3:15 pm Ambulatory Heart Failure Patient – When Has Medical Therapy Failed?, JoAnn Lindenfeld, MD, University of Colorado, Denver, CO

3:30 pm Patient Risk – Heart Failure and VAD Operation – Where is the 'Sweet Spot'?, Garrick C. Stewart, MD, Brigham & Women's Hospital, Boston, MA

3:45 pm MCS in the Less Sick Patients – Where Will REVIVE-IT Fit?, Keith Aaronson, MD, MS, University of Michigan, Ann Arbor, MI

SUBTOPIC: Discuss/Describe the REVIVE-IT Study and Rationale – Clinical Equipoise

4:00 pm PRO-CON: MCS Should Be the First Choice for Patients with End-Stage Heart Failure, Not Transplant.

PRO Joseph Woo, MD, University of Pennsylvania, Philadelphia, PA

CON Andreas Zuckermann, MD, University of Vienna, Austria

4:16 pm Discussion

1:15 pm – 3:15 pm LUNCH BREAK

1:15 pm – 3:30 pm JUNIOR FACULTY MENTOR LUNCH

1:30 pm – 3:00 pm MINI ORAL ABSTRACT SESSIONS

1:30 pm – 3:00 pm COUNCIL MEETINGS

CONCURRENT SYMPOSIA | Thursday

3:15 pm – 4:30 pm

FORUM HALL

CONCURRENT SYMPOSIUM 4

Large and Small Vessels Disease in Heart Transplantation

CHAIRS: Stephan Ensminger, MD, PhD and
Javier Segovia, MD, PhD

Session Summary: Cardiac allograft vasculopathy involves large epicardial and small intramyocardial vessels. Detection of pathological features in both represents a negative prognostic factor. This session will try to focus on the clinical relevance of vasculopathy features that go beyond the mere detection of intimal thickness in either epicardial or small intramyocardial vessels. Finally, can these features be considered therapeutic targets?

3:15 pm *Intimal Thickening vs. Remodeling: Clinical Significance of Volumetric Changes in Epicardial Coronary Arteries*, Luciano Potena, MD, PhD, University of Bologna, Italy

3:30 pm *Microvasculopathy from Artifact to Prognostic Factor*, Elizabeth Hammond, MD, LDS Hospital, Salt Lake City, UT

3:45 pm *From Morphology to Function: Coronary Flow Reserve*, Francesco Tona, MD, PhD, University of Padova, Padova, Italy

4:00 pm *How Can We Ameliorate Microvasculopathy?*, Nicola E. Hiemann, MD, FACC, Deutsches Herzzentrum, Berlin, Germany

4:15 pm *Questions and Answers*

3:15 pm – 4:30 pm

MEETING HALL I

CONCURRENT SYMPOSIUM 5

Tough Situations in Cardiac Transplantation: Bring in the Experts

CHAIR: Mandeep R. Mehra, MD, MBBS, FACC, FACP,
University of Maryland, Baltimore, MD

Session Summary: This session is intended to stimulate a lively discussion on tough problems in the clinical management of long-term heart transplant recipients. Two junior faculty members will present two clinical cases that will be the basis to fire up a discussion between the panelists, welcoming interaction with the audience.

3:15 pm *Case Presentation*, Jennifer A. Cowger, MD, MS,
University of Michigan Health System, Ann Arbor, MI

3:50 pm *Case Presentation Presenter*: Arezu Aliabadi,
MD, Medical University of Vienna, Austria

PANELISTS:

Juan Delgado Jimenez, PhD,
"12 Octubre" University Hospital, Madrid, Spain

Roberto Fiocchi, MD, PhD,
Ospedali Riuniti di Bergamo, Italy

Sudhir S. Kushwaha, MD,
Mayo Clinic, Rochester, MN,

Sean P. Pinney, MD,
Mount Sinai Medical Center, New York, NY

Hermann Reichenspurner, MD, PhD,
University Heart Centre Hamburg, Hamburg, Germany

Marc J. Semigran, MD,
Massachusetts General Hospital, Boston, MA

Hannah A. Valantine, MD,
Stanford University School of Medicine, Stanford, CA

CONCURRENT SYMPOSIA | Thursday**3:15 pm – 4:30 pm**

PANORAMA HALL

CONCURRENT SYMPOSIUM 6*Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel***CHAIRS:** Thomas K. Waddell, MD, MSc, PhD, FRCSC and Paul Corris, MB, FRCP

Session Summary: Transplantation (lung or heart-lung transplantation) in patients with pulmonary arterial hypertension is associated with increased early mortality, and many patients with PAH die while waiting for transplantation. There are many potential reasons for the increased mortality, including universal difficulties with risk prediction, however regional differences in such issues as listing status and organ allocation as well as the type of organ transplantation (lung versus heart-lung) vary tremendously from region to region and these issues may influence outcomes. For this reason, it may be helpful (and certainly interesting) to have representatives from different countries discuss how transplantation for patients with PAH is accomplished in their region. This session will begin with 3 speakers introducing the universal and regional issues regarding timing of referral, listing status, organ allocation, type of organ transplantation and bridging strategies. The introductory presentations will be followed by a longer panel discussion moderated by the session chairs and composed of representatives from various countries to discuss how transplantation for PAH is accomplished in their countries and what they consider to be their challenges and successes. In this way, we learn from each other.

3:15 pm Lung and Heart-Lung Transplantation for PAH: Universal and Regional Issues of Timing of Referral, Listing Status and Organ Allocation, Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX

3:30 pm Bilateral Lung Versus Combined Heart-lung Transplantation for PAH: What are the Considerations for the Type of Operation?, Elie Fadel, MD, Marie Lannelongue Hospital, Paris-Sud, France

3:45 pm Bridging Strategies for Lung Transplant Candidates with PAH: Atrial Septostomy, ECMO, RVAD and Novalung, Duane Davis, MD, Duke University Medical Center, Durham, NC

4:00 pm Lung Transplantation for PAH: Panel Discussion with Transplant Physicians from Various Regions of The World

DISCUSSION: Learning from Each Other – How We Do It Around the World

PANELISTS:

Deborah J. Levine, MD,
University of Texas Health Science Center, San Antonio, TX, USA
Elie Fadel, MD, Marie Lannelongue Hospital, Paris-Sud, France
Prof. Walter Klepetko, MD, Medical University of Vienna, Austria
Teresa De Marco, MD,
University of California, San Francisco, CA, USA
Paul C. Jansz, MD, St. Vincent's Hospital, Australia
Duane Davis, MD,
Duke University Medical Center, Durham, NC, USA

3:15 pm – 4:30 pm

MEETING HALL IV

CONCURRENT SYMPOSIUM 7*Special Considerations: Cystic Fibrosis and Lung Transplantation***CHAIRS:** Cecilia Chaparro, MD and Paul Aurora, MBBS, BSc(Hons), MSc, MRCP, PhD

Session Summary: Cystic fibrosis (CF) remains a common reason for lung transplantation. Patients present special challenges because of complicated microbiology, the systemic nature of the disease, surgical considerations and psychosocial issues. Despite this, when transplants are performed in high volume centers the outcomes are excellent. The session will attempt to highlight special issues in the care of CF transplant patients. This session will be particularly useful to new practitioners in the field with little CF experience, or experienced practitioners in centers where transplants for CF are becoming more common.

3:15 pm Surgical Issues in Lung Transplantation for Cystic Fibrosis, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

3:45 pm Microbiological Issues in Patients with Cystic Fibrosis Undergoing Lung Transplantation, Shahid Husain, MD, MS, University Health Network, University of Toronto, Toronto, Canada

4:15 pm Medical Management of the Lung Transplant Recipient with Cystic Fibrosis, Denis Hadjiliadis, MD, MHS University of Pennsylvania, Philadelphia, PA

CONCURRENT SYMPOSIA | Thursday

3:15 pm – 4:30 pm

MEETING HALL V

CONCURRENT SYMPOSIUM 8

Risky Business: Infectious Risk in Donors and Recipients

CHAIRS: Valentina Stosor, MD and
Kate Gould, FRCPath

Session Summary: When is a patient with hepatitis C a transplant candidate? Is a heart or lung from a hepatitis B core positive donor acceptable? How come that hepatitis E virus causes chronic hepatitis in our transplant patients? And what about these transplant patients that do so well they want to travel the world and will visit the tropics? What are the risks, what precautions do you advise and what should you look for after return? All of this and more, when we discuss the Risky Business of Infections in Transplantation!

3:15 pm *Hepatitis C: When is it a Contraindication?*,
Minh-Hong T. Nguyen, MD, University of Pittsburgh, PA

3:35 pm *Opening the Door to Hepatitis B Core Donors*,
Shirish Huprikar, MD, Mount Sinai School of Medicine, New York, NY

3:50 pm *On the Horizon: Hepatitis E*, Erik A. M. Verschuren, MD, PhD, University Medical Centre Groningen, The Netherlands

4:05 pm *The “Well-Travelled” Donor: What Are The Risks?*, Camille N. Kotton, MD, FIDSA, Massachusetts General Hospital/Harvard Medical School, Boston, MA

3:15 pm – 4:30 pm

NORTH HALL

CONCURRENT SYMPOSIUM 9

Coagulation and Transplantation – The Clot Thickens

CHAIRS: Joren Madsen, MD, PhD and
Stephan Ensminger, MD, PhD

Session Summary: The role of platelets during the development of ordinary arteriosclerosis is established. Interactions of platelets with the endothelium induce significant changes in the adhesive and chemotactic properties of endothelial cells that trigger monocyte adhesion and transmigration. This results in early inflammation during the process of arteriosclerosis within the vessel wall. Platelet activation can occur in the donor or recipient before transplantation as well as during antibody- and cell-mediated rejection. In addition, many patients waiting for transplants have activated platelets due to the diseases that lead to organ failure or as a result of interventions used to support patients before and during transplantation. The contribution of platelets and complement to hyperacute rejection of xenografts is well recognized. Therefore, there is a potential for therapy to inhibit platelet and complement mediated immune stimulation in human transplantation, which will be the main focus of this session.

3:15 pm *The Role of Platelets in the Development of Arteriosclerosis – Relevant Aspects for Transplantation*,
Steffen Massberg, MD, Deutsches Herzzentrum Muenchen, Munich, Germany

3:40 pm *Platelets and Leucocyte Adhesion*, Christian
Weber, MD, LMU University of Munich, Germany

4:05 pm *Complement and T Cell Alloimmunity*, Steven
Sacks, MD, PhD, MRC Centre for Transplantation, King's College
London, United Kingdom

4:30 pm – 5:00 pm COFFEE BREAK/VISIT
EXHIBITS/POSTER VIEWING

5:00 pm – 6:15 pm CONCURRENT ABSTRACT
SESSIONS

5:00 pm – 6:15 pm

NORTH HALL

CONCURRENT SYMPOSIUM 10

Joint ISHLT/IPTA Symposium

CHAIRS: Shaf Keshavjee, FRCS(C) and
Richard Chinnock, MD


6:15 pm – 7:00 pm POSTER VIEWING

FRIDAY, APRIL 20, 2012

7:00 am – 6:00 pm SPEAKER READY
ROOM OPEN

7:30 am – 5:00 pm REGISTRATION DESK OPEN

8:00 am – 9:15 am CONCURRENT
ABSTRACT
SESSIONS

**CONCURRENT SYMPOSIA | Friday****8:00 am – 9:15 am**

MEETING HALL IV

CONCURRENT SYMPOSIUM 11*Management of the Failing Fontan Patient Across the Age Spectrum*

CHAIRS: W. Robert Morrow, MD and
Aditya K. Kaza, MD

Session Summary: Heart transplantation for congenital heart disease is a well-accepted intervention for pediatric cardiologists. However, the single ventricle patient population poses unique challenges even in childhood. This session will address the following key areas of interest:

- 1) Key elements of the cardiac and non-cardiac evaluation for transplantation
- 2) Timing of listing to minimize waitlist mortality and optimize post-transplant outcomes
- 3) Alternate interventions to transplantation and when they should be considered
- 4) Options for mechanical support in a patient with palliated single ventricle anatomy
- 5) Technical surgical challenges to the transplant procedure and how to approach them

8:00 am *How and Why Does the Fontan Circuit Fail?*, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Canada

8:10 am *Is Fontan Conversion a Good Alternative to Transplantation?*, Carl Lewis Backer, MD, Children's Memorial Hospital, Chicago, IL

8:20 am *When to List the Failing Fontan Patient for Transplantation?*, Daniel Bernstein, MD, Stanford University and Packard Children's Hospital at Stanford, Stanford, CA

8:30 am *Plumbing Matters in the Failing Fontan Circulation!*, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:40 am *Challenges in the ICU Post-transplant*, Jane V. Cassidy, MRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:50 am *What are the Post-transplant Outcomes for the Failing Fontan Patient?*, Steven D. Zangwill, MD, Children's Hospital of Wisconsin, Milwaukee, WI

9:00 am – 5:00 pm EXHIBIT HALL OPEN

9:15 am – 9:45 am ANNUAL BUSINESS
MEETING

9:15 am – 9:45 am COFFEE BREAK
VISIT EXHIBITS
POSTER VIEWING

PLENARY SESSION | Friday

9:45 am – 11:15 am

CONGRESS HALL

PLENARY SESSION

The Aging Imperative: Ethics, Economics and Resource Allocation

CHAIRS: Robert L. Kormos, MD, FRCS(C), FAHA and Sharon A. Hunt, MD

Session Summary: The aging of our population impacts health care in multiple domains and affects delivery of care to patients with heart and lung failure. The session will feature Mi-Kyung Song PhD, RN, Associate Professor of Nursing, University of North Carolina, speaking on helping aging patients make decisions regarding health care and Axel Rahmel, Medical Director of Eurotransplant International Foundation, who will speak from a systems perspective. The session will also include presentations on aging and immunobiology, assessment of “frailty” in elderly patients, and the ethics of allocation of scarce resources.

9:45 am *The Impact of an Aging Population on Resources for Healthcare and Transplant*, Axel Rahmel, MD, Eurotransplant International Foundation, Leiden, The Netherlands

10:00 am *Immunobiology – The Immune System from Birth Through End-of-Life*, Daniel R. Goldstein, MD, Yale University School of Medicine, New Haven, CT

10:15 am *How to Incorporate Measures of Frailty in Assessment for Cardiothoracic Surgery*, David J. Lederer, MD, MS, Columbia University, New York, NY

10:30 am *Shared Decision Making in the Aging Population – How to Help Patient Make Decision Right for Them*, Mi-Kyung Song, RN, PhD, University of North Carolina at Chapel Hill, NC

10:45 am *“Accountability for Reasonableness” as an Ethical Framework for Scarce Resource Allocation*, Heather J. Ross, MD, Toronto General Hospital, Toronto, Canada

11:00 am *Featured Abstract Presentation*

CONCURRENT SYMPOSIA | Friday

11:45 am – 1:00 pm

CONGRESS HALL

CONCURRENT SYMPOSIUM 12

MCS Recovery – How Do We Get There?

CHAIRS: Joseph G. Rogers, MD and Hans B. Lehmkuhl, MD

Session Summary: The number of patients with LVADs has been quickly increasing and the number of heart transplants remains without change. Limited clinical data suggest that LVAD unloading, possibly in combination with adjuvant therapies, could lead to myocardial recovery in a subset of patients with advanced heart failure. Better understanding of the direct effects of LVAD unloading on the failing myocardium is needed and may lead to identification and testing of new approaches aimed at myocardial recovery and regeneration. The speakers in this session will discuss our understanding of this process and possible approaches that could make myocardial recovery a treatment goal.

11:45 am *Effects of LVAD Unloading on the Myocardia Function and Structure*, Stavros G. Drakos, MD, Utah Cardiac Transplant Program, Salt Lake City, UT

Noon *Targeted Adjuvant Therapies to Enhance LVAD-Induced Reverse Remodeling*, Emma Birks, MD, PhD, FRCP, University of Louisville, KY

12:15 pm *How to Monitor the Heart During LVAD Unloading*, Simon Maybaum, MD, Montefiore Medical Center, Bronx, NY

12:30 pm *Predictors of LVAD-Induced Sustained Myocardial Recovery*, Michael Dandel, MD, PhD, German Heart Institute, Berlin, Germany

12:45 pm *Panel Discussion*

11:15 am – 11:45 am COFFEE BREAK
VISIT EXHIBITS
POSTER VIEWING

CONCURRENT SYMPOSIA | Friday**11:45 am – 1:00 pm**

FORUM HALL

CONCURRENT SYMPOSIUM 13*The Leading Edge of Immunosuppression in Heart Transplantation: Evidence, Perspectives and Clinical Practice***CHAIRS:** Eulalia Roig, MD and Guatam V. Ramani, MD

Session Summary: The aim of this session is to provide insights from clinical trials and clinical practice of modern immunosuppression, with a brief overview about the future pipeline. The session will be closed by a case-based moderated discussion that will provide a practical context to the preceding lectures.

11:45 am Recent Trials in Immunosuppression – 2, 3 or 1 Drug?, David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ

12:05 pm mTOR Inhibitors as Rescue or First Line Strategy: A Balancing Act, Luciano Potena, MD, PhD, University of Bologna, Italy

12:25 pm Emerging Immunosuppression: Novel Molecules, Maria G. Crespo Leiro, MD, PhD, Hospital Universitario A Coruña, La Caruna, Spain

12:45 pm Putting it Together: A Case Based Moderated Discussion

MODERATOR: Howard J. Eisen, MD, Drexel University College of Medicine, Durham, NC

PANELISTS AND AUDIENCE QUESTIONS AND ANSWERS:

Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
 Guatam V. Ramani, MD, University of Maryland, Baltimore, MD
 David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ
 Luciano Potena, MD, PhD, University of Bologna, Italy
 Maria G. Crespo Leiro, MD, PhD
 Hospital Universitario A Coruña, La Caruna, Spain

11:45 am – 1:00 pm

MEETING HALL I

CONCURRENT SYMPOSIUM 14*Following the RV Through Thick and Thin***CHAIRS:** Felix Perez-Villa, MD, PhD and Lynne W. Stevenson, MD

Session Summary: RV failure is one of the greatest challenges in the management of advanced LV dysfunction. This session will provide a thorough overview of the problem of RV dysfunction in patients with CHF due to LV diseases, with a pathophysiological overview of PH secondary to LV dysfunction, followed by lectures on medical and surgical recommendations to guide the management of RV failure in these patients.

11:45 am Biventricular Failure and Pulmonary Hypertension: A Unique Pathophysiology, Robert P. Frantz, MD, Mayo Clinic, Rochester, NY

Noon Drugs in PH with Left Heart Failure: Role for PH Specific Novel Therapies, Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

12:15 pm Treatment of RV Failure After LVAD or Transplant, Mauro Rinaldi, MD, PhD, University of Turin, San Giovanni Battista, Torino, Italy

12:30 pm Assessment of CRV Function During RV Support, Marc A. Simon, MD, MS, University of Pittsburgh, PA

12:45 pm Panel Discussion

CONCURRENT SYMPOSIA | Friday

11:45 am – 1:00 pm

PANORAMA HALL

CONCURRENT SYMPOSIUM 15

Solving the Enigmatic: Cases in Heart and Lung Transplantation

CHAIRS: Lianne G. Singer, MD, FRCPC and Gerald J. Berry, MD

Session Summary: This proposal expands on the successful inaugural Mid-Day Symposium held in San Diego which attracted 25-30 participants including pathologists and clinicians who provided excellent points of discussion. The format is case-based clinical-pathological correlation (CPC). We will be expanding the format this year to include challenging lung transplant cases. Presenters will include both senior and junior ISHLT members. The moderators will include a clinician and a pathologist to facilitate the discussion. The presenter will provide clinical information and the clinical differential diagnosis will be discussed. The biopsy or autopsy findings will be presented followed by a short discussion of the key morphological points and then an open discussion of salient clinical, radiological, pathological points in diagnosis and management.

11:45 am Cardiac Case #1, Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA

12:05 pm Lung Case #1, Alexandra Rice, FRCPath, London, United Kingdom

12:25 pm Lung Case #2, Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN

12:40 pm Cardiac Case #2, Marny Fedrigo, MD, University of Padua, Italy

11:45 am – 1:00 pm

MEETING HALL IV

CONCURRENT SYMPOSIUM 16

Bad Bugs – What Can We Do?

CHAIRS: Shimon Kusne, MD and Stanley I. Martin, MD

Session Summary: Infections with multi-drug resistant strains are increasingly common in our transplant population. They increase morbidity, mortality and cost for our patients and programs. In this session, the problems with multi-drug resistant pathogens in the context of transplantation will be discussed and illustrated in a case-based format. MDR, VRE, MRSA and the current views on *C. difficile* infection and strategies to prevent infection in our patients will challenge the audience to review their current clinical practice.

11:45 am Multi-Drug Resistant Gram Negative Infections: What Are The Options?, Amparo Sole, MD, PhD, Hospital Universitario y Politecnico le Fe, Valencia, Spain

Noon VRE & MRSA: Can They Be Defeated?, Stanley I. Martin, MD, The Ohio State University Medical Center, Columbus, OH

12:15 pm C. difficile: Can We Keep Our Patients Off the Toilet?, Michele Estabrook, MD, Washington University School of Medicine, St. Louis, MO

12:30 pm Infection Prevention: Get The Bugs Before They Get You!, Frauke Mattner, PhD, Kliniken der Stadt Köln gGmbH, Cologne, Germany

12:45 pm Panel Discussion

CONCURRENT SYMPOSIA | Friday

11:45 am – 1:00 pm

MEETING HALL V

CONCURRENT SYMPOSIUM 17

Pulmonary Hypertension in Chronic Parenchymal Lung Diseases: Does it Matter?

CHAIRS: Marion Delcroix, MD PhD and Reda Girgis, MB, BCh

Session Summary: Pulmonary hypertension is being increasingly recognized as a serious complication of chronic obstructive and interstitial lung diseases. The development of pulmonary vascular disease in these conditions, which is not closely related to the degree of parenchymal involvement, confer greater morbidity and mortality. Several clinical trials of PAH targeted therapies have recently been conducted, but as yet, the role of these agents in this setting remains unclear. This session will provide a state of the art update on the impact of PH in COPD and ILD and potential therapies.

11:45 am Cor Pulmonale in COPD: Not Just Blue Bloaters, Omar A. Minai, MD, Cleveland Clinic Foundation, Cleveland, OH

Noon Importance of Pulmonary Hypertension in ILD, Oksana Anatolia Shlobin, MD, Inova Fairfax Hospital, Heart and Vascular Institute, Fairfax, VA

12:15 pm The Impact of PH in the Lung Transplant Recipient, Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

12:30 pm Therapy for PH Associated with Lung Disease: What is the Evidence?, Pavel Jansa, General University Hospital, Prague, Czech Republic

12:45 pm Panel Discussion

11:45 am – 1:00 pm

NORTH HALL

CONCURRENT SYMPOSIUM 18

Challenges in Pediatric Lung Transplant

CHAIRS: Bart L. Rottier, MD and Melinda Solomon, MD, MSc, FRCP(C)

Session Summary: This session will discuss issues related to Lung Transplantation in the child and young adult. It will also focus on significant challenges that are specific to the younger pediatric population, outline new areas of collaboration such as the use of ECMO and extracorporeal lung assist devices. Lastly, it will focus on retransplantation: who, what, when and where. Is retransplant a good alternative for this patient population?

11:45 am Small But Not Forgotten, Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO

Noon Second Chances: Re-Transplantation in Pediatric Lung Transplantation, Christian Benden, MD, University Hospital Zurich, Switzerland

12:15 pm Bridging to Lung Transplantation in Children, Charles B. Huddleston, MD, St. Louis Children's Hospital, St. Louis, MO

12:30 pm Transition to Adult Care: What Could Pediatricians Do Better?, Joseph M. Pilewski, MD, University of Pittsburgh, Pittsburgh, PA

12:45 pm Panel Discussion

1:00 pm – 3:00 pm LUNCH BREAK

1:15 pm – 2:45 pm MINI ORAL ABSTRACT SESSIONS

1:15 pm – 2:45 pm COUNCIL MEETINGS

CONCURRENT SYMPOSIA | Friday
1:15 pm – 2:15 pm

CONGRESS HALL

CONCURRENT SYMPOSIUM 19

ISHLT/ESOT Joint Symposium

CHAIRS: David O. Taylor, MD (ISHLT) and
Rutger Ploeg, MD (ESOT)

Session Summary: Continuing the theme of learning from prominent members of other transplant societies, this session, jointly sponsored by the European Society of Transplantation, will feature a mixture of clinical, basic and translational science. Presentation topics include: the impact of donation after circulatory death, progress with T-regs, clinical experience with belatacept and the relationship between ABO incompatibility and HLA antibodies.

1:15 pm *Impact of DCD Donors for Thoracic Donation*, Darren Freed, MD, PhD, FRCSC, University of Manitoba, Winnipeg, Canada

1:30 pm *Are TRegs Ready for the Clinic?*, Carla C. Baan, PhD, Erasmus Medical Centre/University Medical Center, Rotterdam, The Netherlands

1:45 pm *Clinical Experience with Belatacept: A Balanced View*, Josep M. Grinyó, MD, University of Barcelona, Barcelona, Spain

2:00 pm *The Impact of ABO Incompatibility on De Novo HLA Ab Production*, Simon Urschel, MD, University of Alberta, Canada

PLENARY SESSION | Friday
3:00 pm – 4:30 pm

CONGRESS HALL

PLENARY SESSION

New Horizons

CHAIRS: Mark L. Barr, MD and
Paul A. Corris, MB, FRCP

Session Summary: Prepare for a glimpse of future research in key areas of relevant to our society. Opening with Harald Ott, MD, Massachusetts General Hospital, describing his work on bioartificial organ rebuilding, and closing with Mandeep Mehra, MD, Professor of Medicine, University of Maryland, speaking on the importance of pulsatile flow in mechanical circulatory support, the session will also include presentations on functional imaging, the future of stem cell research and advances in immunobiology.

3:00 pm *Bioartificial Organs – (Re)Building A New Lung or Heart*, Harald Ott, MD, Massachusetts General Hospital, Boston, MA

3:15 pm *Functional Imaging – New Windows into Allograft Function*, Markus Schwaiger, MD, Klinikum rechts der Isar der TU Muenchen, Munich, Germany

3:30 pm *Stem Cells – Are We There Yet?*, Sonja Schrepfer, MD, PhD, University Heart Centre Hamburg, Germany

3:45 pm *Allograft Tolerance: Can We Find the Path?* Sophie Brouard, PhD, CNRS/Nantes University, Nantes, France

4:05 pm *Why is Pulsatile Flow Important – Is Pulsatility Needed?*, Mandeep R. Mehra, MD, MBBS, FACC, FACP, University of Maryland School of Medicine, Baltimore, MD

4:30 pm – 5:00 pm **COFFEE BREAK
VISIT EXHIBITS
VIEW POSTERS**

5:00 pm – 11:59 pm **EXHIBIT HALL
TEAR DOWN**

5:00 pm – 6:15 pm **CONCURRENT ABSTRACT
SESSIONS**

CONCURRENT SYMPOSIA | Friday

5:00 pm – 6:15 pm

MEETING HALL V

CONCURRENT SYMPOSIUM 20

Self-Management in End-Stage Heart and Lung Disease and Transplantation

CHAIRS: Bronwyn J. Lewey, RN BEd Stu Grad Clin Epi and Nancy P. Blumenthal, CRNP

Session Summary: Improving long-term outcomes in heart and lung transplantation is a priority. Transplantation needs to be seen as a chronic condition as medical dependency is not eliminated and as patients have to manage the therapeutic regimen (e.g. medication), life roles and emotions lifelong. It has been suggested that the implementation of chronic illness management approaches might be the most promising pathway to enhance the long-term outcome. Self-management support is a key component of chronic illness management and has been associated with favorable clinical outcomes.

Self-management support entails more than traditional patient education. It also entails strategies to develop problem-solving skills and to improve self-efficacy. Moreover, support for self-management is embedded in a healthcare system that ensures access to and continuity of care; increasing opportunities for patients to participate in the care process; and coordination of care between settings, which necessitate healthcare system changes into the direction of chronic care.

This symposium aims at clarifying the principles of self-management in heart and lung transplant recipients in view of managing the medical regimen, emotions and new life roles both in adult and pediatric patients in the context of chronic illness management.

5:00 pm *Self-Management as Part of Chronic Illness Management (CIM)*, Christiane Kugler, PhD, University Witten, Dortmund, Germany

5:15 pm *Health Care System Factors Related to Self-Management*, Lut Berben, PhD, RN, Institute of Nursing Science, University of Basel, Basel, Switzerland

5:30 pm *Management of New Life Roles*, Michael G. Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Medical Center-Fairview, Minneapolis, MN

5:45 pm *Self-Management in Pediatrics*, Samantha Anthony, PhD, MSW, RSW, The Hospital for Sick Children/McMaster University, Toronto, Canada

6:00 pm *Self-Management via the Virtual Heart Clinic*, Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, Canada

7:30 pm – 8:30 pm **PRESIDENT'S COCKTAIL RECEPTION**


SATURDAY, APRIL 21, 2012

7:00 am – 1:00 pm **SPEAKER READY ROOM OPEN**

7:30 am – 11:30 am **REGISTRATION DESK OPEN**

8:00 am – 9:15 am **CONCURRENT ABSTRACT SESSIONS**

9:15 am – 9:30 am **COFFEE BREAK**



PLENARY SESSION | Saturday

9:30 am – 11:15 am

FORUM HALL

PLENARY SESSION

Incorporating Information Technology into Pre- and Post-Transplant Care

CHAIRS: Allan R. Glanville, MBBS, MD, FRACP and David O. Taylor, MD

Session Summary: The importance of information technology in health care is expanding in multiple dimensions, including personal and system based electronic health records, the use of social networking to improve patient communication, and the use of information technology to provide more efficient and effective care. The session will open with an overview provided by Cleveland Clinic CMIO Dr. C. Martin Harris and will also include presentations on the use of technology to improve the care of heart failure patients and transplant recipients.

9:30 am Awards Presentations

9:45 am Invited Lecture: Integrating Information Technology into Care: Challenges and Opportunities, C. Martin Harris, MD, Cleveland Clinic, Cleveland, OH

10:15 am Featured Abstract

10:30 am Invited Lecture: Remote Hemodynamic Monitoring, W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH

10:45 am Invited Lecture: Using Technology to Promote Self-Monitoring and Health Outcomes after Transplant, Annette J. DeVito-Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA

11:00 am Invited Lecture: Remote Monitoring of Mechanical Circulatory Support Devices, Jan F. Gummert, MD, Herz- und Diabeteszentrum NRW – Ruhr University Bochum, Bad Deynhausen, Germany

11:15 am – 11:30 am COFFEE BREAK

11:30 am – 12:45 pm CONCURRENT ABSTRACT SESSIONS

1:00 pm – 2:15 pm COUNCIL AND COMMITTEE REPORTS TO THE BOARD AND MEMBERSHIP

2:30 pm – 6:30 pm ISHLT BOARD OF DIRECTORS MEETING

